Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration

Neuropharmacology. 2023 Oct 1:237:109630. doi: 10.1016/j.neuropharm.2023.109630. Epub 2023 Jun 12.


Many patients with Parkinson's disease (PD) experiencing l-DOPA-induced dyskinesia (LID) receive adjunct treatment with dopamine agonists, whose functional impact on LID is unknown. We set out to compare temporal and topographic profiles of abnormal involuntary movements (AIMs) after l-DOPA dose challenges including or not the dopamine agonist ropinirole. Twenty-five patients with PD and a history of dyskinesias were sequentially administered either l-DOPA alone (150% of usual morning dose) or an equipotent combination of l-DOPA and ropinirole in random order. Involuntary movements were assessed by two blinded raters prior and every 30 min after drug dosing using the Clinical Dyskinesia Rating Scale (CDRS). A sensor-recording smartphone was secured to the patients' abdomen during the test sessions. The two raters' CDRS scores were highly reliable and concordant with models of hyperkinesia presence and severity trained on accelerometer data. The dyskinesia time curves differed between treatments as the l-DOPA-ropinirole combination resulted in lower peak severity but longer duration of the AIMs compared with l-DOPA alone. At the peak of the AIMs curve (60-120 min), l-DOPA induced a significantly higher total hyperkinesia score, whereas in the end phase (240-270 min), both hyperkinesia and dystonia tended to be more severe after the l-DOPA-ropinirole combination (though reaching statistical significance only for the item, arm dystonia). Our results pave the way for the introduction of a combined l-DOPA-ropinirole challenge test in the early clinical evaluation of antidyskinetic treatments. Furthermore, we propose a machine-learning method to predict CDRS hyperkinesia severity using accelerometer data.

Keywords: Dyskinesia; Dystonia; Hyperkinesia; Movement disorders; Parkinson's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiparkinson Agents / adverse effects
  • Dopamine Agonists / pharmacology
  • Dyskinesia, Drug-Induced* / diagnosis
  • Dyskinesia, Drug-Induced* / drug therapy
  • Dyskinesia, Drug-Induced* / etiology
  • Dystonia*
  • Humans
  • Hyperkinesis
  • Levodopa / adverse effects
  • Oxidopamine
  • Parkinson Disease* / drug therapy


  • Antiparkinson Agents
  • Dopamine Agonists
  • Levodopa
  • Oxidopamine